These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The adrenergic system and prevention of myocardial damage by beta-blockade: a clinical overview. Cruickshank JM J Cardiovasc Pharmacol; 1989; 14 Suppl 9():S20-4. PubMed ID: 2483227 [TBL] [Abstract][Full Text] [Related]
3. [Changes in lipids and lipoproteins caused by the beta-blocking agents used as antihypertensives]. Rouffy J; Chanu B; Bakir R; Sauvanet JP J Pharmacol; 1983; 14 Suppl 2():183-99. PubMed ID: 6138467 [TBL] [Abstract][Full Text] [Related]
4. Do beta-blockers alter lipids and what are the consequences? Holtzman E; Rosenthal T; Goldbourt U; Segal P J Cardiovasc Pharmacol; 1987; 10 Suppl 2():S86-92; discussion S93. PubMed ID: 2481177 [TBL] [Abstract][Full Text] [Related]
5. Anti-atherosclerotic and plasma lipid lowering effects of the novel calcium blocker with alpha 1-adrenoceptor antagonistic activity, monatepil, in high cholesterol diet-fed Japanese Macaca fuscata monkeys. Miyazaki M; Hosoki K; Okunishi H; Ishii K; Ikeno A; Okazaki Y Arzneimittelforschung; 1994 Mar; 44(3):288-97. PubMed ID: 8192692 [TBL] [Abstract][Full Text] [Related]
6. The emerging problem of plasma lipid changes during antihypertensive therapy. Johnson BF J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S213-21. PubMed ID: 6177959 [TBL] [Abstract][Full Text] [Related]
7. [Lipids, lipoproteins, arterial accidents and oral contraceptives]. Bakir R; Hilliquin P Contracept Fertil Sex (Paris); 1986 Jan; 14(1):81-7. PubMed ID: 12341243 [TBL] [Abstract][Full Text] [Related]
8. Alterations in plasma lipids consequent to endurance training and beta-blockade. Morton AR; Stanforth PR; Freund BJ; Joyner MJ; Jilka SM; Hartzell AA; Ewy GA; Wilmore JH Med Sci Sports Exerc; 1989 Jun; 21(3):288-92. PubMed ID: 2567483 [TBL] [Abstract][Full Text] [Related]
9. [The Göttingen Risk, Incidence and Prevalence (GRIPS) study. Recommendations for the prevention of coronary heart disease]. Cremer P; Muche R Ther Umsch; 1990 Jun; 47(6):482-91. PubMed ID: 2375005 [TBL] [Abstract][Full Text] [Related]
10. [Determination of the usefulness of selected biochemical parameters for assessing the advanced atheromatous changes in human coronary arteries]. Bukowska H Ann Acad Med Stetin; 1998; 44():29-43. PubMed ID: 9857530 [TBL] [Abstract][Full Text] [Related]
11. Effects of calcium antagonists and adrenergic antihypertensive drugs on plasma lipids and cellular cholesterol metabolism. Krone W; Müller-Wieland D; Nägele H; Behnke B; Greten H J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S199-202. PubMed ID: 2455133 [TBL] [Abstract][Full Text] [Related]
12. Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia. Athyros VG; Papageorgiou AA; Avramidis MJ; Kontopoulos AG Coron Artery Dis; 1995 Mar; 6(3):251-6. PubMed ID: 7788039 [TBL] [Abstract][Full Text] [Related]
16. The effects of adrenergic blockade on lipoproteins using the rat as an experimental model. Balasubramaniam S; Simons LA; Hickie JB; Chang S Artery; 1990; 17(2):60-70. PubMed ID: 1968740 [TBL] [Abstract][Full Text] [Related]
17. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Chapman MJ; Guérin M; Bruckert E Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339 [TBL] [Abstract][Full Text] [Related]